How prescribed testosterone safety differs from performance use, what TRAVERSE found, and why blood pressure, fertility and formulation need review.
On this page
Testosterone treatment can be appropriate for some men with confirmed testosterone deficiency, but it is not free of risk. Safety depends on the diagnosis, medical history, formulation and follow up. Evidence about prescribed replacement does not establish the safety of larger amounts used for physique or performance. A reassuring heart trial also does not remove blood pressure, fertility or product specific concerns.
The safety question depends on the setting
| Setting | What informs the decision | What it does not establish |
|---|---|---|
| Confirmed deficiency | Testosterone symptoms, repeated blood tests and the underlying cause | A single low result is not a complete diagnosis |
| Prescribed replacement | Testosterone trial findings plus individual risks and monitoring | Every adverse effect has been excluded |
| Physique or performance use | Replacement trials do not test every testosterone exposure or combination | A safe bodybuilding amount or routine |
| Planning children | Fertility goals need discussion before testosterone treatment | Normal sexual function proves normal sperm production |
Diagnosis comes before a prescription
The Endocrine Society’s 2018 clinical guideline recommends diagnosing hypogonadism, or testosterone deficiency, only when compatible symptoms or signs occur alongside consistently low testosterone concentrations. It recommends repeating a morning fasting measurement and investigating the cause. This connects a laboratory result to the person’s health rather than treating a number alone.
Bring previous test results, symptoms, sleep concerns and a list of medicines to the assessment. Ask what condition is being treated and what improvement would justify continuing. The same guideline calls for review of treatment response and adverse effects. Monitoring is part of treatment, not a promise that every complication can be prevented.
Assess the benefit as well as the risk
Treatment should have a defined goal. A TRAVERSE sexual function study in 1,161 men with low libido found that testosterone gel improved sexual activity and desire compared with placebo, but not erectile function. Participants had hypogonadism and cardiovascular disease or increased cardiovascular risk. The result supports a specific benefit in that group, not a promise to resolve every sexual symptom.
Ask which symptom is expected to improve and how progress will be judged. If the original problem persists, that deserves reassessment rather than assuming that more testosterone is the answer. A treatment decision weighs the expected benefit, burdens of treatment, fertility goals and health risks together.
What TRAVERSE found about cardiovascular events
The TRAVERSE trial, published in 2023, enrolled 5,246 men aged 45 to 80 with symptoms, two low fasting testosterone measurements, and existing cardiovascular disease or high cardiovascular risk. Participants received testosterone gel or placebo. Over an average follow up of 33 months, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 7.0% of the testosterone group and 7.3% of the placebo group.
The trial met its planned standard for ruling out a specified increase in that combined risk. This is not proof of zero risk. Atrial fibrillation (an irregular heart rhythm), acute kidney injury and pulmonary embolism (a blood clot in the lungs) occurred more often in the testosterone group. The results cannot certify lifetime safety, other treatment settings or nonmedical performance use.
FDA warnings changed, but risks remain
In February 2025, FDA announced label changes removing boxed warning language about increased adverse cardiovascular outcomes after reviewing TRAVERSE. It also required warnings about increased blood pressure, based on separate monitoring studies. Removing one warning is not the same as removing all warnings or concluding that testosterone cannot affect the heart.
On June 18, 2026, HHS announced further requested revisions concerning the age related limitation of use and prostate safety wording. The announcement describes proposed changes; it does not establish that every product label has already changed. It also retains uncertainty about prostate effects over longer periods and the need for assessment and monitoring. Ask the prescriber to use the current information for the specific product.
Blood pressure, red cells and clots are distinct concerns
Blood pressure needs checking even when you feel well. The FDA blood pressure findings came from monitoring across the day, separate from the cardiovascular event trial. Ask your prescriber how readings will be followed and what change should prompt contact. A reassuring result on the trial’s combined outcome does not cancel this warning.
The AndroGel label warns about increased hematocrit, the proportion of blood made up of red cells, and reports blood clots. A raised red cell measure needs clinical interpretation and a treatment review. Do not use symptoms alone to judge the result or attempt to manage an abnormal blood count yourself.
Pain and swelling in one leg can be signs of a clot and need urgent assessment. If these occur with chest pain or shortness of breath, seek emergency help. The NHS describes DVT symptoms and care thresholds. These signs have other possible causes, but they should not wait for the next routine blood test.
Fluid retention and other medicines can change risk
Testosterone can promote salt and water retention, causing swelling known as edema. This can be serious in people with heart, kidney or liver disease. The AndroGel prescribing information describes this risk. Tell your clinician about new ankle or body swelling and any existing organ disease.
The same label describes interactions with oral anticoagulants, insulin and corticosteroids. Testosterone can alter anticoagulant effects and blood glucose control; corticosteroids can increase the fluid retention concern. Bring a complete list of medicines and supplements, including diabetes medicines, to the review. Ask the prescriber or pharmacist which checks are needed when treatment starts, changes or stops. Do not adjust those medicines yourself.
Fertility is different from sexual function
Testosterone treatment can suppress sperm production. Improved desire or erections does not establish a normal sperm count. The Endocrine Society’s guideline recommends against starting testosterone in men planning fertility in the near term. Discuss plans for children before treatment, including plans that are uncertain or may change.
Do not assume that stopping will restore fertility on a predictable schedule. A clinician can assess the cause of low testosterone and refer for fertility evaluation when needed. This is a separate discussion from increasing a blood testosterone result, and it does not require you to choose a recovery drug or hormone combination yourself.
Prostate health and urinary symptoms need context
The June 2026 HHS notice says available evidence has not generally shown increased prostate cancer risk with replacement treatment, but follow up may be too short to settle effects that take many years to appear. It also distinguishes mild to moderate prostate enlargement from severe urinary symptoms, for which evidence remains limited. The proposed revisions retain assessment and monitoring; they are not a reason to ignore a prostate history or new symptoms.
Discuss a weak stream, difficulty starting urine, frequent urination or incomplete emptying with a clinician. If you cannot urinate or have severe abdominal pain, seek medical care right away. These are the NIDDK warning signs for urinary retention. A urinary symptom is not itself a cancer diagnosis, and a changed testosterone warning does not explain its cause.
Sleep, skin, hair and breast changes
Testosterone may worsen sleep apnea in some people. The 2018 Endocrine Society guideline advises against starting treatment in untreated severe obstructive sleep apnea. Tell the prescriber about a previous diagnosis and its treatment rather than treating poor sleep as proof that more testosterone is needed.
Breathing pauses, choking or gasping during sleep and persistent daytime tiredness warrant an appointment. Someone who notices your breathing can help describe it. The NHS explains sleep apnea symptoms and assessment. The symptoms can be missed by the person sleeping, so a partner’s observations can be useful.
Reported effects in the gel label include acne, hair loss and application site reactions. Breast enlargement or tenderness can also occur. Report new breast changes, troublesome skin reactions or hair changes to your clinician; do not assume every change is caused by testosterone. The testosterone side effects article covers these adverse effects in greater detail.
Formulations have different precautions
Gel can transfer to another person’s skin. Follow the product’s instructions for hand washing, covering the application area and avoiding contact with children or women. If accidental contact occurs, the exposed skin should be washed with soap and water promptly. These precautions address exposure of others as well as the person prescribed treatment.
The AVEED injection label has a different warning: serious reactions involving oil droplets reaching the lungs and severe allergic reactions. It requires observation in a healthcare setting for 30 minutes after each injection. This requirement belongs to that product; it should not be presented as a rule for all testosterone injections.
Ask about the exact preparation, application or administration precautions, and timing of follow up tests. Gel, injections and other formulations cannot be ranked as universally safest from TRAVERSE alone. A product change needs its own instructions and review, not an assumption that every preparation has the same risks.
Mood changes and stopping treatment
After testosterone use above therapeutic levels, abrupt stopping or a large reduction can produce depressed mood, fatigue, irritability and other withdrawal symptoms. The product label distinguishes this situation from prescribed replacement. Tell a clinician about mood changes and plans to stop so the assessment includes both hormone use and other possible causes.
If you need urgent mental health support, seek it promptly. If you cannot keep yourself or someone else safe, use emergency services immediately. The NHS sets out urgent and emergency mental health care. A withdrawal concern is not a reason to delay help or manage severe symptoms alone.
Make monitoring a plan, not just a blood test
Before treatment, the clinician reviews the diagnosis, fertility goals, cardiovascular and clot history, sleep apnea, urinary or prostate concerns, other illness and medicines. After starting, review should address the original symptom, adverse changes and the results needed for the selected product. Ask who receives each result and how you will hear about any action required.
- Testosterone measurements help assess treatment exposure; sampling time depends on the formulation.
- Blood pressure and blood counts address different risks and should not be treated as interchangeable.
- Prostate assessment and PSA testing should follow the individual’s age, history and agreed monitoring plan.
- Changes in sleep, mood, sexual function, urinary symptoms and skin or breast tissue belong in the review alongside numbers.
Normal results on one occasion do not guarantee future safety. Testing also does not establish a safe nonmedical regimen. Our page on blood tests for anabolic steroid users explains the purpose and limits of common checks without treating a result as personal clearance.
Choose urgent, prompt or routine care
Use emergency services for the warning signs described above, including persistent sudden chest discomfort or inability to stay safe. Seek urgent assessment for a possible leg clot or inability to pass urine. Bring new or worsening symptoms to the prescriber promptly; keep routine reviews even if you feel well. Our emergency warning signs page brings the care routes together.
If use has been nonmedical, tell the clinician what you took, when you took it and any other substances involved. You can use our page on talking to a doctor about anabolic steroid use to prepare. The aim is an informed medical assessment, not clearance from a trial result or a changed warning label.